THE Therapeutic Goods Administration (TGA) has adopted Access Consortium guidance for fast-tracking authorisations of modified COVID-19 vaccines (COVAX) for variants.
The coalition of regulatory authorities from Australia, Canada, Singapore, Switzerland and the UK, set out information that medicines regulators would need to approve any modifications to authorise COVAX, should virus mutations make them less effective.
"According to the guidance, vaccine manufacturers would need to provide robust evidence that the modified vaccine produces an immune response, but time-consuming clinical studies that do not add to the regulatory understanding of a vaccine's safety, quality or efficacy are unlikely to be needed," the TGA said.
"This is because researchers are now better able to measure protection by looking at antibodies in the blood following vaccination, reducing the need to wait and see whether or not people in a trial become infected with the disease.
"This would significantly reduce the length of time taken for the modified vaccine to be ready for use.
"Alongside data on the immune response, the vaccine manufacturer would also be expected to provide evidence showing the modified vaccine is safe and is of the expected quality.
"In addition, data from the original robust clinical trials and the ongoing studies on real-world use in millions of people couldbe used to support any decision by the regulators.
"This approach is based on the tried and tested regulatory process used for seasonal flu vaccines, for which annual modifications are needed to match the strains circulatingeachyear."
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Mar 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Mar 21
